How Should We Reposition Against Substitutes in Healthtech / Digital Health?
Direct answer: In healthtech, your most dangerous competitor is rarely another app — it's the substitute your buyer already trusts: the status quo (nurse phone triage, a spreadsheet, an EHR module, or "do nothing"). To reposition against substitutes, map the real decision space on the two axes your buyer actually weighs — usually clinical/economic proof and workflow integration effort — then move your product toward an uncontested position where a substitute is structurally weak. Use a Competitive Positioning Map to make that space visible, pick a defensible corner, and rebuild your messaging, pricing, and roadmap around it.
Disclosure: This article is published by Percision (percision.app), an AI-powered strategic intelligence platform. We reference our tool where relevant and are explicit about when a spreadsheet or human consultant is the better call.
Why Substitutes Beat Competitors in Digital Health
Healthtech founders usually benchmark against direct rivals: other remote-monitoring vendors, other patient-engagement platforms, other AI-scribe tools. That's the wrong fight. In most healthtech sales cycles, the deal is lost not to a competitor but to a substitute:
- A hospital keeps using manual chart review instead of your AI triage.
- A payer sticks with an existing case-management vendor bundled into their platform.
- A clinic decides the ROI doesn't justify another login and stays with fax and phone.
Substitutes win because they carry near-zero switching cost, no procurement friction, and no new HIPAA/security review. Your differentiation is real, but it's priced in a currency (feature depth) the buyer discounts against a currency they care about (proven outcomes, minimal disruption, reimbursement clarity).
Repositioning means changing which axes the buyer uses to compare you — and choosing a position where the substitute looks like the risky option, not you.
Building the Competitive Positioning Map for Healthtech
A Competitive Positioning Map plots every option — competitors and substitutes — on two axes that reflect the buyer's true decision criteria. The discipline is choosing the right axes, then being honest about where you actually land.
Step 1 — Define the buyer and the job. Positioning shifts by segment. A CMIO buying an AI diagnostic aid weighs clinical validation; a practice manager buying scheduling software weighs staff-hours saved. Pick one buyer per map. Don't average.
Step 2 — Choose two axes that decide the sale. For healthtech, the most revealing pairs are usually:
- Clinical/economic proof (anecdote → peer-reviewed evidence → reimbursement code) vs. Integration effort (rip-and-replace → light API → EHR-embedded).
- Or Regulatory readiness (wellness tool → FDA-cleared) vs. Breadth of use case.
Avoid vanity axes like "innovation" or "quality." Use axes a buyer would defend in a budget meeting.
Step 3 — Plot honestly, including substitutes. Place the status quo, adjacent EHR modules, incumbents, and yourself. What "good" looks like: the map has an obvious empty corner where buyer demand exists but no option — including the substitute — serves it well.
Step 4 — Test the corners. For each open position ask: Is there a real buyer segment here? Can we credibly reach it with our current tech and evidence? Does moving here weaken the substitute's advantage (e.g., an EHR-embedded position kills the "another login" objection)?
Step 5 — Choose and re-tool. A repositioning is only real when messaging, pricing, roadmap, and sales motion all move to the chosen corner. If your website still leads with "AI-powered engagement platform" while your winning position is "the only reimbursable remote-monitoring tool that lives inside Epic," you haven't repositioned — you've redecorated.
What "Good" Looks Like — and Common Traps
A strong healthtech repositioning usually does one of three things against substitutes:
- Neutralizes switching cost by embedding into the workflow the substitute owns (integration axis).
- Reframes the risk so the substitute becomes the liability — e.g., "manual review misses X% of high-risk patients" backed by your validation, not invented industry stats.
- Attaches to money by aligning with an existing reimbursement pathway or documented cost line, so the buyer isn't buying software — they're capturing revenue or avoiding penalty.
Traps to avoid: mapping only against other startups (ignoring the status quo), choosing axes that flatter you, and repositioning marketing without repositioning the roadmap. Regulators and clinical buyers punish claims you can't substantiate, so every proof-axis position must be defensible.
Where Percision Fits — and Where It Doesn't
Running a rigorous positioning exercise takes structured thinking, competitor and substitute research, and translation into a plan. That's where a strategic intelligence platform helps.
Percision runs your business context through 83 structured reasoning steps across 27+ frameworks — including the Competitive Positioning Map — and returns board-ready output in roughly 7–15 minutes: candidate axes, a plotted map of competitors and substitutes, defensible open positions, and a first-draft repositioning plan with financial framing (DCF, ratios, warning signs). It's a co-pilot, not an autopilot — your leadership team validates the clinical and regulatory claims, which no model should assert on its own.
Broader context: studies like the 2023 BCG–Harvard field experiment found generative AI meaningfully improved consultants' speed and quality on suitable tasks — while also showing accuracy dropped on tasks outside the tool's competence. Treat Percision the same way: excellent for structuring the analysis and stress-testing options, not a substitute for your clinical, legal, or reimbursement expertise.
When you don't need Percision: if you have one clear segment and two obvious axes, a whiteboard and a spreadsheet get you there. If your challenge is deep FDA regulatory strategy, payer contracting, or a bet-the-company pivot, hire a specialist healthtech consultant. Percision is strongest when you need consulting-grade structure fast, across many scenarios, without an 8–12 week engagement.
You can run a Competitive Positioning Map analysis at percision.app.
What this looks like when the analysis is actually run
The substitute here is not a competitor. It is the payer deciding to run the programme itself on a flat fee.
The subject is Vantabridge Health, a sample company profile we use for testing rather than a customer: a virtual chronic-care platform, $62M revenue, 340,000 enrolled members.
Excerpt from a real Percision run · Cost Reduction (T7) · sample company profile
The fallback the plan names. Pivot to a fixed-fee PMPM model with optional 15% upside sharing only — triggered if more than 3 of the 8 Q4 2026 contract renewals demand a PMPM reduction above 15% to accept the 25% cap, or if outcome-prediction accuracy falls below 70% on the 10k cohort by Month 9.
The position being defended instead. A 25% downside cap with 30% upside participation above baseline, anchored on 34 existing contracts representing 71% of revenue, an 11-month sales cycle and 48-month durability that allow phased renegotiation over 18 months without channel loss.
What makes the position credible. A connected-device data stream from 340k enrolled members supplying 1.4M longitudinal data-years of outcome-prediction accuracy, currently 75% on the 10k cohort.
What it is worth. $2.9M of gross profit protected annually; runway from 2.3 to 3.4 years; composite portfolio durability from 48 months to 52.
The odds the plan gives itself. A 0.7 probability that health plans accept the cap without demanding a 15–20% PMPM reduction to compensate.
| Phase | Gate metric | Target | Deadline |
|---|---|---|---|
| Foundation (0-6 months) | Board approval of 25% cap contract template | Unanimous board consent | Month 3 |
| Traction (6-18 months) | ≥6 of 8 Q4 2026 contracts renew at 25% cap with ≤5% PMPM reduction | 75% renewal success rate | Month 18 |
| Scale (18-36 months) | ≥80% of 34 contracts renewed at 25% cap; data licensing pilot generates ≥$500K ARR | 80% renewal + $500K licensing ARR | Month 36 |
A 0.7 on the central assumption is the most useful number in the run. There is close to a one-in-three chance the payers simply price the cap back — they take the reduced downside and pay less per member for it, leaving Vantabridge with lower revenue and the same economics.
Naming the fixed-fee PMPM fallback in advance is what makes that acceptable. If the market wants to buy a service rather than an outcome, that is a real product with real margin; the failure mode is discovering it during a renewal with no template drafted.
Read a complete Percision report — every page, no email required.
FAQ
What's the difference between a competitor and a substitute in healthtech? A competitor solves the same job the same way (another remote-monitoring vendor). A substitute solves the job differently — manual triage, an EHR module, or doing nothing. Substitutes usually win deals because they carry no switching cost, so they belong on your map.
Which axes should a digital health company use for its positioning map? The ones your buyer defends in a budget meeting — typically clinical/economic proof versus integration effort, or regulatory readiness versus use-case breadth. Avoid "innovation" or "quality" axes that flatter you but don't drive purchase decisions.
Can AI do our repositioning for us? It can structure the map, plot options, and draft a plan quickly — but clinical claims, regulatory posture, and the final strategic call must stay with your leadership. Use AI as a co-pilot; keep humans accountable for anything a payer, regulator, or clinician will scrutinize.